Trius Therapeutics (TSRX) Announces Notice of Allowance of U.S. Patent Application Related to Tedizolid Phosphate Combination With Daptomycin
5/13/2013 9:47:18 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, May 13, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) on an application related to its tedizolid phosphate patent portfolio. This newly allowed patent application protects a therapeutic combination of the experimental medicine tedizolid phosphate with a currently available antibiotic daptomycin. Data show that together, the medicines can uniquely prevent the development of daptomycin non-susceptible bacterial strains such as methicillin-resistant Staphylococcus aureus (MRSA).
Help employers find you! Check out all the jobs and post your resume.
comments powered by